Skip to main content
. 2012 Oct 9;15(1):78–84. doi: 10.1208/s12248-012-9417-7

Table I.

Parameters for Individual Everolimus and Sorafenib Effects on Pancreatic Cancer Cells

Cell line Drug R 0 (%) (CV%) IC50 (CV%) I max (CV%) γ (CV%)
MiaPaCa-2 Everolimus 95.67 (3.43) 4.51 (32.16) nM 0.39 (12.31) 1.52 (46.31)
Sorafenib 88.31 (4.81) 8.29 (6.25) μM 1.00 (Fixed) 3.3 (20.57)
Panc-1 Everolimus 102.5 (2.85) 3.87 (13.83) nM 0.41 (6.45) 2.53 (27.23)
Sorafenib 100.3 (2.49) 6.58 (5.51) μM 1.00 (Fixed) 2.1 (12.38)